Promising new target for cancer chemotherapy identified by UCSD and Swedish researchers

December 17, 2001

Researchers at the University of California, San Diego (UCSD) School of Medicine, in conjunction with colleagues from Lund University in Sweden, have identified in the laboratory a promising new target for cancer chemotherapy that could impact tumor formation and metastasis by inhibiting cell growth. The findings are reported in the December 18 issue of the Proceedings of the National Academy of Sciences (PNAS).

The research team, led by Jeffrey D. Esko, Ph.D., professor of Cellular and Molecular Medicine and associate director of the UCSD Glycobiology Research and Training Center, reports that tumor growth was blocked in vitro and in laboratory mice by interfering with a cell's ability to supply itself with vital substances called polyamines.

Cells depend on polyamines for growth. Because these substances play an essential role in cell proliferation, two pathways exist to ensure an adequate supply. Cells produce their own internally, and they gather circulating polyamines that come from dietary sources, such as intestinal bacteria, and those excreted by other cells.

In this study, the researchers showed that a cell-surface sugar molecule called heparan sulfate is critical to the cell's uptake of circulating polyamines. They also showed that if the internal production of polyamines is blocked, through use of a well-known inhibitor drug called DFMO (difluoromethylornithine), the cell continues to proliferate by simply increasing its external gathering function. Finally, using a heparan sulfate inhibitor that decreased the formation of the cell surface sugar molecules, they demonstrated that inhibiting both of the cell's supply pathways for polyamines resulted in a dramatic reduction in tumor formation in an experimental model of metastasis.

"This paper demonstrates the principle that inhibiting the production of heparan sulfate and blocking the pathway of polyamine formation provides a combination therapy for treating tumors," said Esko, who is also a member of the Rebecca and John Moores UCSD Cancer Center. "The heparan sulfate inhibitor that we developed worked reasonably well. Now that we've proven the principle, we need to develop better inhibitors."

DFMO is a well-known and well-tolerated drug traditionally used as an anti-parasitic, but is now being studied in clinical trials as a chemopreventive agent in at-risk individuals for a variety of cancers.
In addition to Esko, the research was conducted by first author Mattias Belting, M.D., Ph.D., Lars-Ake Fransson, M.D., Ph.D., and Lo Persson, M.D., Ph.D., Lund University, Sweden; Mark M. Fuster, M.D., UCSD Department of Medicine; and Jillian R. Brown, Ph.D., UCSD Department of Cellular and Molecular Medicine.

The research was funded by grants from International Union Against Cancer, Swedish Cancer Fund, the Tobacco-Related Disease Program at the University of California, and the US National Institutes of Health.

University of California - San Diego

Related Medicine Articles from Brightsurf:

An ultrasonic projector for medicine
A chip-based technology that modulates intensive sound pressure profiles with high resolution opens up new possibilities for ultrasound therapy.

A new discovery in regenerative medicine
An international collaboration involving Monash University and Duke-NUS researchers have made an unexpected world-first stem cell discovery that may lead to new treatments for placenta complications during pregnancy.

How dinosaur research can help medicine
The intervertebral discs connect the vertebrae and give the spine its mobility.

Graduates of family medicine residencies are likely to enter and remain in family medicine
This study provides an overview of the characteristics of physicians who completed family medicine residency training from 1994 to 2017.

Nuclear medicine and COVID-19: New content from The Journal of Nuclear Medicine
In one of five new COVID-19-related articles and commentaries published in the June issue of The Journal of Nuclear Medicine, Johnese Spisso discusses how the UCLA Hospital System has dealt with the pandemic.

Moving beyond 'defensive medicine'
Study shows removing liability concerns slightly increases C-section procedures during childbirth.

NUS Medicine researchers can reprogramme cells to original state for regenerative medicine
Scientists from NUS Medicine have found a way to induce totipotency in embryonic cells that have already matured into pluripotency.

Protein injections in medicine
One day, medical compounds could be introduced into cells with the help of bacterial toxins.

Study reveals complementary medicine use remains hidden to conventional medicine providers
Research reveals that 1 in 3 complementary medicine (CM) users do not disclose their CM use to their medical providers, posing significant direct and indirect risks of adverse effects and harm due to unsafe concurrent use of CM and conventional medicine use.

Study of traditional medicine finds high use in Sub-Saharan Africa despite modern medicine
Researchers who have undertaken the first systematic review of into the use of traditional, complementary and alternative medicines (TCAM) in Sub-Saharan Africa found its use is significant and not just because of a lack of resources or access to 'conventional medicine'.

Read More: Medicine News and Medicine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to